Furthermore, a study using a mouse model of dilated cardiomyopathy highlighted the cardioprotective efficacy of HDAC6 inhibitors, suggesting their potential as a therapeutic approach for cardiomyopathy and various forms of heart failure (Yang et al., 2022). This evidence concerns the gene HDAC6 and heart failure.